Preventive medications are drugs taken to lower the chance of a future illness or complication, rather than to treat symptoms that are already present. Some familiar examples include vaccines and medicines for high blood pressure; less-discussed options include HIV pre-exposure prophylaxis, preventive migraine therapies, and medicines that reduce the risk of severe allergic reactions. Their value depends on a person’s risk, health history, and preferences: the U.S. Preventive Services Task Force recommends low-dose aspirin for primary prevention only selectively, while CDC guidance identifies HIV PrEP as a highly effective option for people who may be exposed. This overview explains how preventive medicines are assessed, highlights overlooked categories, and outlines questions to discuss with a clinician.
How preventive medications are defined and evaluated
The National Cancer Institute describes chemoprevention as the use of medicines or other agents to reduce the risk of cancer or delay its development. More broadly, preventive medication includes prescribed drugs used before a condition occurs or before an established condition causes a foreseeable complication. Examples range from antiviral prophylaxis to statins for people at elevated cardiovascular risk. These medicines are not interchangeable: each has a particular target, evidence base, eligibility criteria, and potential harms.
Clinicians commonly distinguish primary prevention, which aims to prevent a first event, from secondary prevention, which aims to prevent recurrence or progression after a diagnosis or event. Decisions weigh absolute benefit against adverse effects, treatment burden, cost, and the likelihood that a person will take the medicine consistently. A relative-risk reduction can sound impressive while the absolute benefit remains small when baseline risk is low, so individualized risk assessment matters.
Risk assessment and shared decisions
A preventive prescription is most useful when a person’s chance of the target outcome is high enough to justify treatment. Age, family history, prior illness, lab results, other medicines, pregnancy potential, and personal priorities can all change that calculation. The USPSTF, for example, recommends that adults aged 40 to 75 with at least one cardiovascular risk factor and a 10-year cardiovascular risk of 10% or greater be offered a statin for primary prevention; for risk between 7.5% and less than 10%, it recommends selectively offering one. These are population recommendations, not a substitute for a clinician’s assessment.
Overlooked preventive medications for infection and cancer risk
Some preventive drugs are tied to a defined exposure or elevated inherited or clinical risk. They can be highly effective when the right person starts them at the right time, but require testing, monitoring, or a clear plan for stopping. Prevention medication generally complements—not replaces—vaccination, screening, safer practices, and other recommended care.
HIV pre-exposure prophylaxis
Pre-exposure prophylaxis, or PrEP, is HIV medicine taken by a person who does not have HIV to reduce the chance of acquiring it. CDC states that PrEP, when taken as prescribed, reduces the risk of getting HIV from sex by about 99%; oral PrEP also reduces risk from injection drug use by at least 74%. Options include daily oral medicines and long-acting injections. Before starting, a clinician tests for HIV and assesses kidney health and hepatitis B status where relevant; follow-up testing is essential because PrEP does not prevent other sexually transmitted infections. CDC advises clinicians to inform all sexually active adults and adolescents about PrEP and to prescribe it to anyone who asks, following evaluation.
Hepatitis B post-exposure prevention
After a qualifying exposure to hepatitis B, preventive care may include hepatitis B vaccine and, in some situations, hepatitis B immune globulin (HBIG), which supplies antibodies for immediate, temporary protection. CDC guidance says the combination and timing depend on the exposed person’s vaccination and antibody status and the source’s infection status. Because prevention is time-sensitive, a needlestick, sexual exposure, or other possible contact should be assessed promptly by a healthcare professional rather than handled through self-treatment.
Preventive medication for people at elevated cancer risk
Risk-reducing medicines may be considered for selected people with elevated cancer risk. For example, the USPSTF recommends that clinicians offer tamoxifen, raloxifene, or aromatase inhibitors to women aged 35 or older who are at increased breast-cancer risk and at low risk for adverse medication effects. It does not recommend these medicines routinely for women who are not at increased risk. Potential harms differ: tamoxifen and raloxifene can increase blood-clot risk, while tamoxifen also raises the risk of endometrial cancer in people with a uterus. A formal risk assessment and discussion of personal and family history are central to deciding whether benefits outweigh harms.
Preventive medications for cardiovascular and neurologic events
For chronic diseases, prevention often means reducing the likelihood of a first serious event or limiting the consequences of a condition already identified. These medicines work best as part of a broader plan that may include monitoring, nutrition, physical activity, and treatment of other risk factors.
Statins for cardiovascular risk reduction
Statins lower LDL cholesterol and reduce the risk of cardiovascular events in appropriately selected patients. The USPSTF’s recommendation for adults aged 40 to 75 uses both a cardiovascular risk factor—such as dyslipidemia, diabetes, hypertension, or smoking—and estimated 10-year risk to guide treatment. Someone with a previous heart attack or stroke is generally considered for secondary prevention under separate clinical guidance. Muscle symptoms and drug interactions can occur, so the choice of statin and dose should account for other conditions and medicines.
Low-dose aspirin: not a routine choice for everyone
Low-dose aspirin can reduce clot-related events but also increases bleeding risk. The USPSTF recommends an individualized decision for adults aged 40 to 59 who have at least a 10% 10-year cardiovascular risk and are not at increased bleeding risk; it recommends against starting aspirin for primary prevention in adults aged 60 or older. This is specifically about starting aspirin for a first cardiovascular event—not a direction to stop aspirin prescribed after a heart attack, stroke, or another established indication. Anyone considering a change should consult the prescribing clinician.
Preventive migraine treatment
Migraine prevention uses regular medicines to reduce headache frequency, severity, or disability, rather than treating an individual attack. The American Headache Society identifies preventive treatment as an option when migraine causes substantial burden, acute medicines are ineffective or overused, or attacks are frequent. Options may include certain blood-pressure medicines, antiseizure medicines, antidepressants, CGRP-targeting therapies, or botulinum toxin for chronic migraine. The right choice depends on headache pattern, other health conditions, pregnancy considerations, side effects, and patient preference; treatment is periodically reviewed to assess benefit.
Preventive medicines for severe allergy and other specific risks
Some preventive medicines are designed for people with a known, recurring hazard rather than for the general population. In these cases, an emergency plan and correct use of medication can be as important as the prescription itself.
Epinephrine for anaphylaxis preparedness
An epinephrine auto-injector is prescribed to people at risk of anaphylaxis, a rapid, potentially life-threatening allergic reaction. It is not a daily medicine that prevents an allergy from occurring; it is rescue medication intended for immediate use when anaphylaxis is suspected, followed by emergency medical care. The American College of Allergy, Asthma & Immunology advises people at risk to carry their prescribed device and know how to use it. A clinician or allergist can help determine whether a prescription, a second device, and an individualized emergency action plan are appropriate.
Travel-related malaria prevention
Malaria chemoprophylaxis means taking an antimalarial medicine before, during, and after travel to a destination where malaria occurs. CDC guidance emphasizes that the drug depends on destination-specific resistance patterns, trip length, medical history, and pregnancy status. Medication should be combined with mosquito-bite prevention, such as repellent, protective clothing, and screened or netted sleeping areas. Travelers should consult a travel-health clinician before departure because some regimens must begin days or weeks ahead, and fever during or after travel warrants urgent medical assessment.
How to make preventive medication safer and more effective
Preventive treatments only help when they are matched to the right indication and used correctly. A practical discussion with a healthcare professional can clarify the expected benefit, alternatives, monitoring, and how long treatment is intended to continue.
- Ask what specific event or illness the medicine is intended to prevent and how your personal risk was estimated.
- Discuss absolute benefit, likely side effects, interactions, pregnancy or breastfeeding considerations, and what monitoring is required.
- Confirm how and when to take the medicine, what to do about missed doses, and when to seek urgent care.
- Review the plan periodically, especially after a new diagnosis, a change in other medicines, or a major change in health or exposure risk.
- Do not start, stop, or share prescription medication without professional advice; preventive medicines can be harmful when used for the wrong person or purpose.
Conclusion: prevention works best when it is personal
Preventive medication spans HIV PrEP, exposure-related hepatitis B prevention, selected cancer-risk reduction, statins, carefully considered aspirin, migraine prevention, epinephrine preparedness, and travel-related malaria prophylaxis. The shared principle is not that everyone should take more medicine, but that people with a meaningful, defined risk should know which evidence-based options may reduce it. Ask a clinician or pharmacist to review your risks and current medicines, and use trusted guidance from organizations such as CDC, the USPSTF, and specialty medical societies to support—not replace—that conversation.
Sources: Centers for Disease Control and Prevention, Clinical Guidance for PrEP, https://www.cdc.gov/hivnexus/hcp/prep/index.html; Centers for Disease Control and Prevention, Hepatitis B Virus Postexposure Management, https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html; U.S. Preventive Services Task Force, Breast Cancer: Medication Use to Reduce Risk, https://www.uspreventiveserv icestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction; U.S. Preventive Services Task Force, Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication; U.S. Preventive Services Task Force, Aspirin Use to Prevent Cardiovascular Disease, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication; National Cancer Institute, Chemoprevention, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemoprevention; American Headache Society, The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice, https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14153; American College of Allergy, Asthma & Immunology, Anaphylaxis, https://acaai.org/allergies/management-treatment/anaphylaxis/; Centers for Disease Control and Prevention, Choosing a Drug to Prevent Malaria, https://www.cdc.gov/malaria/hcp/drug-malaria/index.html.